Cowen & Co

Cephalon (NASDAQ: CEPH) stock rose $16.45 this morning, stopping at $75.20 a share after a hostile takeover bid of approximately $5.7 billion from Valeant Pharmaceuticals International (NYSE: VRX). Cephalon's surge is Nasdaq's biggest intraday gain since April 2000. Cephalon's surge of...

Analysts at Cowen & Co upgrade Savient Pharmaceuticals Inc (NASDAQ: SVNT) from "neutral" to "outperform." The target price for SVNT is set to $19. SVNT's shares gained 10.08% to close at $12.67 yesterday. More Analyst Ratings here

Analysts at Cowen & Co upgrade Goodrich Corporation (NYSE: GR) from "neutral" to "outperform." GR's shares gained 1.89% to close at $79.34 yesterday. More Analyst Ratings here

Analysts at Cowen & Co upgrade AnnTaylor Stores Corp (NYSE: ANN) from "underperform" to "neutral." ANN's shares lost 1.48% to close at $20.58 yesterday. More Analyst Ratings here

Bloomberg has quoted unidentified sources as saying that Genzyme (NASDAQ: GENZ) has refused the takeover offer from Sanofi-Aventis (NYSE: SNY). GENZ is, maybe, holding out for a better offer. Analyst Phil Nadeau of Cowen & Co said that it is just a matter of time, “given that Genzyme has...

Analysts at Cowen & Co maintain their "neutral" rating on Isis Pharmaceuticals (NASDAQ: ISIS). Isis and GlaxoSmithKline (NYSE: GSK) have collaborated as a result of which ISIS will develop a maximum of six antisense candidates for rare and serious diseases. Cowen & Co does not consider the...

Analysts at Cowen & Co downgrade Synaptics (NASDAQ: SYNA) from "outperform" to "neutral," while lowering their estimates for the company. According to Cowen & Co, the downgrade in the rating is based on slower growth in the handset segment. The analysts expect Synaptics to maintain its...

Analysts at Cowen & Co maintain their "outperform" rating on United Therapeutics (NASDAQ: UTHR). United Therapeutics reported Q4 revenues ahead of expectations, driven by strong Tyvaso revenues. Earnings missed expectations due to higher SG&A and R&D expenses, the analysts say. “We...

Analysts at Cowen & Co maintain their "outperform" rating on Gilead Sciences Inc (NASDAQ: GILD). Numerical data from the Phase II proof-of-concept studies of Gilead Sciences’ Quad Combo pill and GS9350, GILD’s proprietary PK booster, were solid. The results “provide us with increased confidence...

Analysts at Cowen & Co maintain their "neutral" rating on Alliant Techsystems (NYSE: ATK). Cowen & Co believes that the consensus revenues and EPS for Alliant Techsystems will be lowered for 2H10, as NASA’s F11 budget request seeks to terminate the “Constellation” program and retire the...